Compositions and methods useful for the treatment of h-abc leukodystrophy
AssigneeThe Children's Hospital of Philadelphia
InventorsAdeline VANDERVER, Sunetra SASE, Akshata ALMAD
Life of this patent
Estimating the term…
Abstract
Compositions and methods for the treatment of H-ABC leukodystrophy are disclosed.
Claims20
A method of lowering TUBB4A levels in targeted cells, thereby improving symptoms of H-ABC leukodystrophy in a patient in need thereof, the method comprising administration of a therapeutically effective amount of a composition comprising a synthetic inhibitory nucleic acid molecule targeting TUBB4A, wherein lowering TUBB4A levels in said cell and reducing one or more of
- i) delayed motor development;
- ii) cognitive dysfunction;
- iii) gait dysfunction;
- iv) ataxia;
- v) intention tremor;
- vi) dysarthria;
- vii) dysphonia;
- and
- viii) aberrant hypomyelination;
- in said patient, wherein the synthetic nucleic acid molecule is selected from an antisense oligonucleotide, an shRNA, an siRNA, and a guide strand suitable for CRISPR editing TUBB4A targeted nucleic acids.
A method of treating, delaying the onset of, ameliorating, and/or reducing a disease, disorder and/or condition, or a symptom thereof, associated with H-ABC leukodystrophy in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a synthetic nucleic acid targeting TUBB4A, wherein the disease, disorder and/or condition, or the symptom thereof, associated with H-ABC leukodystrophy is treated, inhibited, the onset delayed, ameliorated, and/or reduced in the patient, wherein the synthetic nucleic acid molecule is selected from an antisense oligonucleotide, an shRNA, an siRNA, and a guide strand suitable for CRISPR editing.
The method of 6, wherein the disease, disorder and/or condition is associated with hypomyelination.
A composition for reducing expression of TUBB4A, comprising a synthetic nucleic acid molecule targeting, and specifically hybridizing to, a TUBB4A encoding nucleic acid, selected from an antisense oligonucleotide, an shRNA, an siRNA, and a guide strand suitable for CRISPR editing in a biologically acceptable carrier.
The composition of 12, wherein said synthetic nucleic acid molecule is present in a vector.
The composition of 12 formulated for single intracerebroventricular (ICV) bolus injection.
Dependencies are inferred from the claim text.